NCT04162366View on ClinicalTrials.gov

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

July 15, 2021

Conditions
HypertensionRenal Insufficiency, Chronic
Interventions
DRUG

Aprocitentan 25 mg

Tablet, oral use once daily

DRUG

Placebo

Matching placebo tablet, oral use once daily

Sponsors

Collaborators (1)

Janssen Biotech, Inc.
All Listed Sponsors
collaborator

Janssen Biotech, Inc.

INDUSTRY

lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT04162366 - A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. | Biotech Hunter | Biotech Hunter